UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specif ...

Guardant Health (GH) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Hello, everybody, and welcome to the Garden Health Q1 twenty twenty five Earnings Call. My name is Elliot, and I'll be your coordinator today. I would now like to hand over to Zarek Khorshid, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you. Earlier today, Guardant Health released financial results for the quarter ended 03/31/2025. Joining me today from Guardant are Helmy Altuchi, Co CEO Amir Aline Talasa ...

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% PALO ALTO, Calif. April 30, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights ...

Guardant Health (GH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on April 30, 2025, might help the stock move higher if these key numbers are better than ex ...

Guardant Health, Inc. (NASDAQ: GH ) is a biopharma company working on liquid biopsy tests for several illnesses, but mostly with a focus on oncology applications. Basically, their approach relies on genomic and digital technology to analyze patients' DNA samples andMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate ...

On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.’s GH Shield blood test for colorectal cancer (CRC) screening.The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening.Medicare already covers the test.For Medicare patients beginning April 1, the Shield test will be reimbursed at $1,495 during the initial nine-month ADLT period.Also Read: What ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Guardant Health (GH) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Guardant Health is one of 1009 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector grou ...

Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Pa ...

Conquering Cancer with Data Q4 2024 & Full Year 2024 Earnings Call February 20, 2025 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance ...

Core Insights - Guardant Health reported a strong revenue growth of 30% year-over-year, reaching $201.8 million, surpassing analysts' expectations of $192 million [2][3] - The company experienced a non-GAAP loss of $0.62 per share, which was better than the anticipated loss of $0.75 per share, while the net loss narrowed to $111 million [2][3][6] Business Overview and Focuses - Guardant Health specializes in precision oncology, focusing on advanced blood tests for cancer detection and management, particularly through liquid biopsies [4] - The company is prioritizing product innovation and strategic partnerships to enhance research capabilities and market access, with a focus on securing payer reimbursement [4][8] Quarterly Highlights and Developments - The precision oncology segment saw a 30% increase in sales, contributing $184.6 million to total revenue, aided by new Medicare reimbursement rates [5] - Operating expenses rose to $250.2 million, primarily due to increased spending on R&D, sales, and marketing, although the net loss was reduced due to the absence of a prior-year legal expense [6] Regulatory and Strategic Collaborations - Guardant Health achieved regulatory approvals, including Medicare coverage for its Guardant Reveal Smart Liquid Biopsy, enhancing its service offerings [7] - Collaborations with industry leaders like Boehringer Ingelheim and ConcertAI support the company's research initiatives and commitment to innovation [7] Future Projections - For 2025, Guardant Health anticipates revenue growth of 15% to 16%, projecting revenues between $850 million and $860 million, with oncology revenue expected to grow by approximately 15% [9] - The company aims to stabilize its non-GAAP gross margin between 62% and 63% and plans to control cash burn, projecting $225 million to $235 million for the year [9][10]